Chronic kidney disease affects roughly 850 million people worldwide, yet most disease-modifying therapies have been validated primarily in diabetic populations. This landmark Phase III trial directly challenges the assumption that finerenone's proven kidney-protective effects are diabetes-dependent, potentially expanding the treatment-eligible population by tens of millions.
This randomized, placebo-controlled trial enrolled 1,584 adults without diabetes who had CKD with moderate-to-severe albuminuria (urinary albumin-to-creatinine ratio 200–3,500 mg/g) and an eGFR between 25 and 90 ml/min/1.73 m², all receiving background renin-angiotensin system inhibition. Participants received finerenone at 10 or 20 mg daily or placebo for up to 32 months. The primary endpoint — total eGFR slope from baseline — and secondary composite endpoints encompassing kidney failure, significant eGFR decline, heart failure hospitalization, and cardiovascular death were assessed using a two-slope mixed-effects model. The mean baseline eGFR was approximately 46.7 ml/min/1.73 m², placing the cohort firmly in moderate-to-severe CKD territory.
This finding carries considerable weight in the nephrology landscape. Finerenone's selectivity as a nonsteroidal mineralocorticoid receptor antagonist differentiates it mechanistically from older steroidal agents like spironolactone, offering anti-inflammatory and antifibrotic activity with a more favorable hyperkalemia and gynecomastia profile. Prior FIDELIO-DKD and FIGARO-DKD trials established its efficacy in diabetic CKD, but non-diabetic CKD — encompassing IgA nephropathy, hypertensive nephrosclerosis, focal segmental glomerulosclerosis, and other etiologies — represents a massive unaddressed burden. If the eGFR slope and composite event data confirm benefit, this trial could be practice-changing, supplementing or complementing SGLT2 inhibitors (already approved across CKD regardless of diabetes status). Key limitations include moderate cohort size, the 32-month follow-up horizon, and heterogeneity within the non-diabetic CKD category. The practical and regulatory implications, however, are potentially paradigm-shifting for nephrology.